Metraipolis › archive › dc_a43cd747f7c7
Advaxis — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Advaxis
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-07T16:22:21.411Z
- SHA-256 of the archived text
285ffa212fc5d0af0e7693f017f23ef96743253260cba587d834e239250875e1- Stable URL of this page
https://metraipolis.com/documento/dc_a43cd747f7c7
How to cite
Advaxis — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Advaxis (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_a43cd747f7c7 (Metraipolis archive dc_a43cd747f7c7, sha256 285ffa212fc5d0af0e7693f017f23ef96743253260cba587d834e239250875e1)
BibTeX
@misc{dca43cd747f7c7,
title = {Advaxis — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Advaxis},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_a43cd747f7c7; sha256 285ffa212fc5d0af0e7693f017f23ef96743253260cba587d834e239250875e1},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Advaxis. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Advaxis Immunotherapies Inc. was an American company that focused on the discovery, development, and commercialization of immunotherapies based on a genetically engineered platform based on Listeria monocytogenes (aka Lm). The company merged with Ayala Pharmaceuticals, with the newly formed company beginning operations under the name Ayala Pharmaceuticals in January 2023. The Lm-based platform on which the company's products were based involves the use of an attenuated Lm, which secretes an antigen/adjuvant fusion protein and stimulates a patient's immune system (specifically their T cells) to mount an immune response to the secreted antigen. If the antigen is specifically found on cancerous cells, the result is an immune response targeting and eliminating the cancer. Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies. The company had over fifteen constructs in various stages of development, both directly and through strategic collaborations with centers, such as the National Cancer Institute, Cancer Research UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security,among others. The company also had a veterinary medicine program that was evaluating an Lm-LLO-based immunotherapy in a Phase 1 study in canine osteosarcoma. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «Advaxis» — https://en.wikipedia.org/wiki/Advaxis Wikidata Q4686419: «American immunotherapy technology development company» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q4686419 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Advaxis?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1379523749, consultata il 2026-11-07T16:17:50.720Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 292a3077ec4f969249e442e362574d31666935b7345fc348c01bd1a55fe139bd